| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_39770248238389dd869fdaef87983879 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2570-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6848
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B20-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B20-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B20-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate |
2018-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8fbef2f5c21dd2ee23ea5c34b91d76b7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5bfc25b37dd0a2a2aa5e578c0c10a33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c40666f5652bbca51d006753f508e36c |
| publicationDate |
2020-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20200013731-A |
| titleOfInvention |
INVESTIGATING TUMORAL AND TEMPORAL HETEROGENEITY THROUGH COMPREHENSIVE -OMICS PROFILING IN PATIENTS WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER |
| abstract |
The molecular profile of metastatic tumors can be determined more accurately using a combination of DNA mutation profiles and RNA expression profiles of selected genes that exhibit substantial changes in anti-tumor treatment. Such combination information can be used to determine differential pathway activity that may be associated with sensitivity or resistance to anti-tumor treatment. |
| priorityDate |
2017-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |